Evidence map›Paper›PMID 40283924›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

PEGylated Liposomes of Disulfiram and Paclitaxel: A Promising Chemotherapeutic Combination Against Chemoresistant Breast Cancer.

Ammar Said Suliman, Sahrish Rehmani, Benjamin Small, Kate Butcher, Mouhamad Khoder, Vinodh Kannappan, Weiguang Wang, Abdelbary Elhissi, Mohammad Najlah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ammar Said SulimanPharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK.
Sahrish RehmaniPharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK.
Benjamin SmallFaculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.ORCID 0000-0002-5104-2150
Kate ButcherFaculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Mouhamad KhoderSchool of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston Upon Thames, London KT1 2EE, UK.ORCID 0000-0002-7640-471X
Vinodh KannappanFaculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Weiguang WangFaculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.ORCID 0000-0003-0509-2605
Abdelbary ElhissiDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar.
Mohammad NajlahPharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK.ORCID 0000-0001-7670-2859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast tumorschemoresistant cancercytotoxicitydisulfirampaclitaxelPEGylated liposomes

Identifiers

PMID40283924
PMCPMC12030275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.